Indeed, in accordance with the in vitro data, LRIG1 displayed a decreased expression in patient derived xenograft that proved to be resistant to EGFR blockade (tumor volume increase of at least 35% compared to the initial pre-treatment volume). This evidence concerns the gene LRIG1 and neoplasm.